

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#15

Inventor: Chroboczek et al.

Confirmation No.: 2330

Appl No.: 09/530,560

Group Art Unit: 1636

Filed: May 2, 2000

Examiner: D. Guzo

For: TRANSFECTING PEPTIDE VECTOR, COMPOSITION CONTAINING
SAME AND THEIR APPLICATIONS

RECEIVED

AUG 21 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, DC 20231ELECTION

In response to the requirement for restriction mailed July 2, 2002, Applicants elect the peptide vector comprising:

- a segment of an NLS sequence including SEQ ID NO: 2 (X₀KRAR) in which X₀ represents an alanine (A),
- a hydrophobic sequence consisting of SEQ ID NO: 7 in which X₁ represents LSTS (SEQ ID NO: 10) and X₂ represents EDES (SEQ ID NO: 16), and
- a polymeric sequence of basic amino acids.

This election is made with traverse. Applicants submit that the peptide vectors as claimed relate to a single inventive concept, for the reasons set forth more fully below.

Therefore, Applicants request reconsideration and withdrawal of the requirement for restriction.

The subject matter of claims 1 and 2 is a peptide vector comprising a transfecting peptide derived from the fibre of an adenovirus, comprising:

1. a segment of an NLS chosen from a segment of an adenovirus fibre (SEQ ID NO: 1 to 6) or a segment of the SV40 virus VP3 protein (SEQ ID NO: 24),
2. a hydrophobic sequence derived from an adenovirus fibre presenting the sequence X₁-F(D/N)PVYPY-X₂ (SEQ ID NO: 7-8), said vector also comprising or being associated to:
3. a polymeric sequence of basic amino acids or a cationic polymeric sequence or a polyalcohol.

Claims 1 and 2 define alternatives according to the so-called Markush practice.

According to Section (f)(i)(B)(1) of Annex B of the Administrative instructions under the PCT which is cited by the Examiner, as regards the interpretation of Rule 13.2 PCT in the situation wherein a single claim defines alternatives, Unity of Invention shall be considered to be

satisfied when a common structure i.e. a significant structural element is shared by all of the alternatives.

According to Section (f)(ii) of the same Annex B "significant structural element is shared by all alternatives" refers to cases where the compounds may have in common only a small portion of their structures (which may be a single component or combination of individual components linked together), providing that the commonly shared structure constitutes a structurally distinctive portion in view of existing prior art.

The claimed alternatives as claimed in claims 1 and 2 fulfill the requirements of Rule 13.2 PCT for the following reasons.

1) The claimed alternatives share a common structural element

The claimed vectors have in common a portion of their structure which is a combination of an NLS sequence linked to an hydrophobic sequence presenting the motif X₁-[F(D/N)PVYPY]-X₂ which is derived from an adenovirus fibre; this common structural element is illustrated by figure 7.

Thus the claimed alternatives share a common structural element.

2. The claimed alternatives share a significant structural element

It will be seen from the present International Application, for example from Table II page 19, that the hereabove defined common structural element (NLS sequence linked to an hydrophobic sequence presenting the motif X₁-[F(D/N)PVYPY]-X₂) solves the problem of the invention, i.e. to find a composition capable of efficiently transfecting eukaryotic cells, in the absence of liposomes and of the treatment of cells.

Thus the common structural element shared by the alternatives is a significant structural element.

3. The claimed alternatives share a structurally distinctive portion in view of the prior art.

The hereabove defined common structural element (NLS sequence linked to an hydrophobic sequence presenting the motif X₁-[F(D/N)PVYPY]-X₂) is novel and not obvious in view of the prior art which uses different transfection peptides:

- a cationic polymer, a basic polymer and an NLS sequence (International Application WO 96/25508),

- a cationic lipid and an acidic peptide (International Application WO 97/30170),
- a fusion protein consisting of a cellular factor and a basic polycationic peptide (European Application EP 0 544 292),
- a peptide representing a membrane receptor ligand, a NLS sequence and a basic peptide (International Application WO 94/23751),
- a polymer of basic amino acids and an NLS sequence derived from the SV40 T antigen or the adenovirus Ela or Elb proteins, linked by a neutral amino acid hinge sequence (International Application WO 95/31557), or
- an adenoviral complex (12 pentons or 12 penton bases) and an attachment peptide derived from the N-terminal region of the adenovirus fibre, comprising a carboxyterminal polylysine or a polyarginine (International Application WO 97/18317).

Thus, the claimed alternatives share a significant structural element which is distinct from the prior Art.

Therefore, the claimed alternatives meet the requirement of Unity of invention (Rule 13.2 PCT), according to Section (f)(i)(B)(1) and (ii) of Annex B of the Administrative instructions under the PCT.

Consequently, the vectors as claimed in claim 1 and claim 2 form a single general inventive concept (Rule 13.1 PCT).


Respectfully submitted,



Raymond O. Linker, Jr.
Registration No. 26,419

CUSTOMER NO. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Charlotte Office (704) 444-1000
Fax Charlotte Office (704) 444-1111
#4548287v1

I hereby certify that this correspondence is being deposited with the United States Postal service with sufficient postage as first class mail, in an envelope addressed to the Commissioner for Patents, Washington, DC 20231 on August 12, 2002



Joyce D. Smith